2024
New opportunities for theranostics research in stroke
KUCHYNKA, Michaela; Jan BISKUPIČ; Magdaléna ONUŠČÁKOVÁ; Peter SCHEER; Jana HLOŽKOVÁ et al.Základní údaje
Originální název
New opportunities for theranostics research in stroke
Název česky
NOVÉ MOŽNOSTI PRO VÝZKUM TERANOSTIK U CÉVNÍ MOZKOVÉ PŘÍHODY
Název anglicky
New opportunities for theranostics research in stroke
Autoři
KUCHYNKA, Michaela; Jan BISKUPIČ ORCID; Magdaléna ONUŠČÁKOVÁ; Peter SCHEER ORCID; Jana HLOŽKOVÁ a Viktor KANICKÝ
Vydání
CHEMICKÉ LISTY, Praha, Czech Society of Chemical Engineering, 2024, 0009-2770
Další údaje
Jazyk
čeština
Typ výsledku
Článek v odborném periodiku
Obor
10400 1.4 Chemical sciences
Stát vydavatele
Česká republika
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 0.400
Označené pro přenos do RIV
Ano
Kód RIV
RIV/00216224:14160/24:00138553
Organizační jednotka
Farmaceutická fakulta
UT WoS
EID Scopus
Klíčová slova česky
cévní mozková příhoda, teranostika, laserová ablace, nanočástice
Klíčová slova anglicky
stroke; theranostic; laser ablation; nanoparticles
Příznaky
Recenzováno
Změněno: 27. 2. 2025 09:22, Mgr. Marie Novosadová Šípková, DiS.
V originále
Stroke, myocardial infarction, and pulmonary embolism represent a significant health burden for modern society, with their primary causes being blood clots and damage to the endothelial lining of blood vessels. Accurate and rapid diagnosis of these clots, particularly determining their age, is crucial for optimal treatment selection, such as thrombolysis (pharmacological dissolution of the clot) or thrombectomy (mechanical removal of the clot). However, existing diagnostic methods do not achieve the required levels of accuracy and efficiency. This article explores the potential of iodinated nanoparticles (IoNPs) based on polyiodinated biodegradable polymers, which can selectively target specific components such as fibrin, thereby enabling visualization of blood clots using X-ray imaging techniques like computed tomography (CT) or fluoroscopy. The nanoparticles have the capability not only to visualize clots but also to estimate their age, which could significantly support a modern theranostic approach that combines diagnosis and therapy. The article also demonstrates the possibilities of testing the pharmacokinetics of these theranostics using a model organism (rat), employing the method of laser ablation inductively coupled plasma mass spectrometry (LA-ICPMS). This approach contributes to a better understanding of the biodegradability of potential therapeutics and represents a key step in preclinical evaluation.
Anglicky
Stroke, myocardial infarction, and pulmonary embolism represent a significant health burden for modern society, with their primary causes being blood clots and damage to the endothelial lining of blood vessels. Accurate and rapid diagnosis of these clots, particularly determining their age, is crucial for optimal treatment selection, such as thrombolysis (pharmacological dissolution of the clot) or thrombectomy (mechanical removal of the clot). However, existing diagnostic methods do not achieve the required levels of accuracy and efficiency. This article explores the potential of iodinated nanoparticles (IoNPs) based on polyiodinated biodegradable polymers, which can selectively target specific components such as fibrin, thereby enabling visualization of blood clots using X-ray imaging techniques like computed tomography (CT) or fluoroscopy. The nanoparticles have the capability not only to visualize clots but also to estimate their age, which could significantly support a modern theranostic approach that combines diagnosis and therapy. The article also demonstrates the possibilities of testing the pharmacokinetics of these theranostics using a model organism (rat), employing the method of laser ablation inductively coupled plasma mass spectrometry (LA-ICPMS). This approach contributes to a better understanding of the biodegradability of potential therapeutics and represents a key step in preclinical evaluation.
Návaznosti
| MUNI/C/0002/2023, interní kód MU |
|